EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and …
T Takano, T Fukui, Y Ohe, K Tsuta… - Journal of Clinical …, 2008 - ascopubs.org
Purpose This study evaluated whether the presence of epidermal growth factor receptor
(EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic …
(EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic …
Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma …
Background Mutations in the epidermal growth factor receptor (EGFR) have been
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors
Y Taniguchi, A Tamiya, K Nakahama… - Oncology …, 2017 - spandidos-publications.com
The aim of the present study was to analyze the impact of metastatic status on the prognosis
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …
EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology …
I Okamoto, T Kashii, Y Urata, T Hirashima… - Journal of Clinical …, 2006 - ascopubs.org
7073 Background: Recently several retrospective analyses have reported that somatic
activating mutations in the EGFR tyrosine kinase domain underlie responsiveness to …
activating mutations in the EGFR tyrosine kinase domain underlie responsiveness to …
First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …
T Shukuya, T Takahashi, R Kaira, A Ono… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
[HTML][HTML] Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
S Watanabe, Y Minegishi, H Yoshizawa… - Journal of thoracic …, 2014 - Elsevier
Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …
M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results …
T Otsuka, M Mori, Y Yano, J Uchida… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth
factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and …
factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and …
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H Asahina, K Yamazaki, I Kinoshita, N Sukoh… - British journal of …, 2006 - nature.com
Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …